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Chapter:  Pathogenicity factors in group C and G Streptococci 
Claire E. Turner, Laura Bubba and Androulla Efstratiou 
This chapter is dedicated to the memory of Professor Singh Chatwal, an inspiring streptococcologist 
who leaves us with wonderful memories of Lancefield 2002 held in Goa, India.  
INTRODUCTION 
The pyogenic streptococci of Lancefield groups C and G were initially recognized as a cause 
of animal infections long before they were even considered as agents of human disease, even 
though they are widely distributed in animals and humans. They comprise a heterogeneous 
complex of streptococcal species that act as causative agents of a spectrum of diseases 
ranging from mild pharyngitis, skin infection to life threatening systemic infections 
associated with high mortality rates.  In this chapter we provide an overview of the various 
group C and group G streptococcal species, the diseases they cause, and the major 
pathogenicity factors that contribute towards their virulence (Table 1).  
TAXONOMY AND IDENTIFICATION 
Taxonomic classification of group C streptococci (GCS) and group G streptococci (GGS) has 
always proven to be a complex issue. However, extensive taxonomic studies over the last few 
years have distinguished most of the veterinary pathogens belonging to Lancefield groups C 
and G from the human pathogens. Previously, GCS and GGS were divided into the following 
species, Streptococcus equisimilis (only GCS, human pathogen), Streptococcus sp. (GGS, 
human pathogen), Streptococcus dysgalactiae (GCS, animal pathogen), Streptococcus equi 
(animal GCS), Streptococcus zooepidemicus (animal and human GCS), Streptococcus canis 
(animal GGS), the Streptococcus anginosus group and Streptococcus phocae (1). GCS and 
GGS of human origin are now considered to constitute a single subspecies, Streptococcus 
dysgalactiae subsp equisimilis. Therefore, the current taxonomy characterises the species as follows; 
S. dysgalactiae is divided into the subspecies S. dysgalactiae subsp. equisimilis and S. 
dysgalactiae subsp. dysgalactiae (hereafter referred to in this chapter as S. equisimilis and S. 
dysgalactiae).  Streptococcus equi is divided into the subspecies S. equi subsp. equi and S. 
equi subsp. zooepidemicus (hereafter referred to as S. equi and S. zooepidemicus).  On the 
basis of genetic evidence, Streptococcus dysgalactiae, Streptococcus equi, Streptococcus 
canis are more closely related to each other than to the S. anginosus group, and constitute 
species with the large-colony colony phenotype. Recent data now suggests that S. equi may 
simply be a subclone of S. zooepidemicus (2). S. phocae is a new species expressing the 
group C antigen thus far only isolated from seals (3, 4). Some of these species may also 
contain strains which express the Lancefield group A or group F antigens (Table 2). 
HUMAN DISEASE AND DIAGNOSIS 
GCS and GGS can cause a wide range of diseases from mild to severe, both among human 
and animal populations. GCS and GGS generally colonize the human respiratory, 
gastrointestinal and genitourinary tracts, with an estimated <4% asymptomatic pharyngeal 
carriage rate in adults (5-7). Human invasive infections caused by GCS and GGS have been 
associated with underlying conditions, such as diabetes, cardiovascular diseases and chronic 
skin conditions (8-10). While S. dysgalactiae is considered an animal pathogen, S. equisimilis 
is almost exclusively a human pathogen, with increasing prevalence and overlaps in clinical 
manifestations with group A Streptococcus (GAS). S. equisimilis infections include acute 
pharyngitis, pneumonia, endocarditis, cellulitis, peritonitis, septic arthritis, bacteraemia, and 
toxic shock syndrome (11-23). Like GAS, S. equisimilis has also been linked to the post 
streptococcal sequelae rheumatic heart disease, and in high endemic areas of rheumatic fever, 
carriage rates of GCS/GGS have been found to be higher than GAS (24, 25).  
Infections with S. zooepidemicus and S. canis, normally considered zoonotic species, have 
also been reported in humans (26-29), including severe infective endocarditis (30). 
Generally, person to person transmission of GCS/GGS occurs via respiratory droplets or skin 
contacts, however, other zoonotic vehicles of transmission such as unpasteurized milk 
products are also possible (26, 27, 31).  
S. dysgalactiae predominantly resides in domestic animals such as cattle, sheep, cats, and 
dogs that either constitute healthy carriers of the bacterium or go on to develop diseases such 
as pneumonia, arthritis, septicemia, and abscesses, particularly bovine mastitis. S. equi, a 
pathogen primarily restricted to horses and donkeys, causes strangles which is a highly 
contagious disease characterized by purulent discharges from the respiratory tract and the 
development of abscesses (32). This organism is not considered to be part of the normal flora 
because of its close association with disease. In contrast, S. zooepidemicus is an opportunistic 
commensal that colonizes mucosal surfaces, and causes rhinopharyngitis, pneumonia (33), 
endometritis, neonatal septicemia, and wound infections in horses (34) as well as disease in 
other domestic animals such as cattle, sheep, pigs, and chicken. Although uncommon, S. 
zooepidemicus is also responsible for a range of zoonotic infections in humans (26, 27). 
The small-colony phenotype of group C and G streptococci is expressed by the Streptococcus 
anginosus group, formerly known as Streptococcus milleri. The group contains three species 
Streptococcus anginosus, Streptococcus constellatus, and Streptococcus intermedius (1).  
Strains belonging to the S. anginosus group express group antigens F, C, A and G, or no 
antigen.  These strains are also likely to be non-beta-hemolytic.  Members of these species 
are recognized as common commensal organisms of the human oral cavity, gastrointestinal 
tract, and genitourinary tract.  They are also associated with access formation in the mouth 
and other bodily sites (35, 36) as well as pharyngitis (37) and endocarditis (38, 39). It has also 
been reported that S. anginosus, along with Streptococcus mitis and Treponema denticola can 
be isolated from esophageal cancer tissue and by initiating inflammation in the cancerous 
tissue have a role in the development or progression of these cancers (40, 41).  
Several assays are available to detect, classify and genetically describe group C and group G 
streptococci. Routine microbiological diagnosis follows the same guidelines in use for the 
identification of the other beta-haemolytic streptococci (BHS) (42). The BHS isolates are 
divided into large and small colonies forming groups based on the growth on sheep blood 
agar: the large-colony-forming group are pyogenic. The small colony forming species 
comprise the anginosus group and are not referred to as GCS or GGS even though they may 
cross react with C or G sera. Lancefield agglutination tests are still used to group BHS into 
the Lancefield groups. Fermentations tests are used to classify GCS as S. equisimilis or S. 
zooepidemicus and are based upon a spectrum of biochemical tests which are now available 
commercially (43). More recently, matrix-assisted laser desorption ionization-time of flight 
mass spectrometry (MALDI-TOF-MS) has been described as a rapid alternative for the 
identification of streptococci (44). In addition, multilocus sequence analysis (MLSA) of 
seven housekeeping genes (45) and other sequenced based assays are performed to analysis 
the streptococcal phylogenies. In particular, sequencing of the emm gene, that encodes the 
hyper-variable surface protein M, and 16s rRNA genes is undertaken for phylogenetic 
analysis of these streptococci based upon sequence similarities (46, 47). 
Next generation sequencing is increasingly being used for genetic characterization, 
phylogenetic analyses, virulence and pathogenicity profiles and antibiotic resistance analyses 
(22, 48). S. equisimilis and S. pyogenes (or GAS) share a high genetic similarity (~72%) and 
similar virulence genes, suggesting a common evolutionary origin and genetic exchange (22, 
25, 49).  
 
MECHANISMS FOR ADHERENCE 
S. equisimilis causes a similar spectrum of disease in humans to S. pyogenes and molecular 
studies have demonstrated virulence determinants that are almost identical. Putative virulence 
determinants of S. equisimilis include adhesins, toxins, and factors that are essential for 
dissemination in human tissues and for interference with the host immune responses.  
Adhesion of microorganisms to host tissues represents a critical phase in the development of 
infection. It is therefore unsurprising that micro-organisms have evolved dedicated 
mechanisms for attachment and adherence to extracellular matrix (ECM) components of the 
host (50, 51).  Of these components the high-molecular-weight glycoprotein fibronectin 
appears to be the major attachment target of Gram-positive cocci, including group G 
streptococci and group C streptococci.  Fibronectin itself is responsible for substrate adhesion 
of eukaryotic cells via specific cell surface factors of the integrin family. It also specifically 
interacts with other matrix components, such as collagen, fibrin, and sulfated 
glycosaminoglycans demonstrating this molecule fulfills multifunctional roles within the 
extracellular network (52). Being present in the extracellular matrix of most tissues, as well 
as in plasma and other body fluids in its soluble form, fibronectin represents an exquisite 
target for bacteria to exploit the cell attachment properties of this molecule by linking the 
pathogen to specific target cells. Epithelial cells of the upper respiratory tract of humans are 
bathed in secretions containing fibronectin in its soluble form. Once bound to the bacterial 
surface, it will enable the pathogen to attach and subsequently colonize the primary site of 
infection.  
Fibronectin binding proteins (FBPs) were first identified in Staphylococcus aureus and S. 
pyogenes (53) and approximately eleven have been defined in S. pyogenes, highlighting their 
importance for this pathogen (54). Binding by these bacteria to eukaryotic cells via 
fibronectin is also an important preliminary event prior to the invasion of these cells (55-57). 
The FBPs from streptococci and staphylococci share a common architecture, with a putative 
signal sequence at the N terminus and a wall- and membrane-spanning region. The major 
fibronectin binding domains are located within the C-terminal part of the proteins and are 
composed of 3 to 5 repetitive units that consist of 35 to 37 amino acid residues and bind to 
the 29kDa N-terminal fragment of fibronectin.  Further binding studies of PrtF/SfbI from S. 
pyogenes, and FnBPA in S. aureus also indicate the presence of a secondary fibronectin 
binding sites upstream of the repeat regions (53).   
The first FBPs to be identified group C and G streptococci were FnbA and FnbB from S. 
dysgalactiae (58). FnbA can opacify serum as well as bind fibrinogen, like the serum opacity 
factor of S. pyogenes (59).  Both FnbA and FnbB bind fibronectin through C-terminal repeat 
regions (50).   
Three FBPs have been defined in S. zooepidemicus: FNZ, FNZ2 and SFS. Although the 
modular organization of FNZ, a S. zooepidemicus FBP, is similar to those from other species, 
homology at the amino acid level is weak (60). Fibronectin binding is mediated through a 
repeat region and a second upstream region containing the amino acid motif LAGESGET.  
This motif is also present in the secondary binding domain of SfbI (61) where it acts 
independently from the repeat region in binding to fibronectin (62). This domain is also 
present in GfbA, the homologue of SfbI in S. dysgalactiae (63). fne is the homologous gene 
to fnz in S. equi (64).  However FNE is unique in that a single nucleotide deletion in fne gene 
has resulted in the truncation of the protein and so, with the loss of the cell-wall binding 
motif, it is secreted into the surrounding environment.  The truncated FNE also lacks the 
classic fibronectin binding repeats found in the C-terminal region of FNZ, but is able to bind 
fibronectin through amino-half domain, also found in FNZ. Consequently, fibronectin 
binding at the bacterial surface is much lower for S. equi than S. zooepidemicus although both 
have an additional cell wall anchored FBP; FNEB and FNZ2 (65). FNZ2 has both collagen 
and fibronectin binding properties (66). SFS of both S. equi and S. zooepidemicus strains and 
contains a signal peptide, but no cell-wall binding motifs, or the traditional fibronectin 
binding motifs.  SFS inhibits binding between fibronectin and collagen. If SFS were to bind 
fibronectin attached to bacterial surface through FNEB/FNZ/FNZ2 this may inhibit binding 
of fibronectin to collagen, which could have several physiological consequences (67).  
Some of the FBPs and also collagen binding proteins identified in S. pyogenes are 
chromosomally located within the Fibronectin and Collagen binding proteins and T antigen 
encoding (FCT) locus. There are at least 9 different types of FCT regions within S. pyogenes 
that vary by gene content and order, but within this region are the genes required to make the 
pili. The pilus has been shown to contribute to the formation of biofilm and mediate 
adherence to host cells (68-71). Whole genome sequence analysis of group C and G 
streptococci have also identified potential FCT regions. One putative pilin locus, FimI exists 
within the genome of S. equi strain 4047 (72). Although no pili structures have been 
identified for S. equi, the proteins of FimI are expressed during growth and have the potential 
to affect adherence in vivo (73). The gene encoding the collagen binding protein CNE of S. 
equi (74) is present within this FimI locus.  A homologous locus was also found within S. 
zooepidemicus isolates, as well as an additional one or two potential pili loci (72, 75). Two 
FCT regions were also found in S. equisimilis, that share high levels of genetic identity to 
FCT regions from different S. pyogenes genotypes, suggesting multiple horizontal gene 
transfer events (22, 76).  
An alternative for group C and G streptococci to adhere to host cells is via binding to other 
ECM molecules including fibrinogen, vitronectin, laminin, collagen and plasminogen (77, 
78). The M-protein like fibrinogen binding protein of G streptococci (FOG) can act as an 
adhesin by binding collagen IV (79) and has been shown to also bind collagen I fibrils in 
dermis in vivo (80).   
Vitronectin is a multifunctional serum protein that affects the humoral immune system by 
binding to and inhibiting the complement membrane attack complex (81) and is also a major 
matrix-associated adhesive glycoprotein that regulates blood coagulation. The ability of 
group C and G streptococci specifically interact with vitronectin (82) and mediate the 
adherence to both epithelial and endothelial cells (83, 84) was demonstrated sometime ago. 
However a specific vitronectin binding protein has never been identified in streptococci.   
ANTIPHAGOCYTIC FACTORS 
A major requirement of pathogenic streptococci is to be able to resist phagocytosis. The 
streptococcal M protein, first identified and characterized in S. pyogenes, is the major 
antiphagocytic factor (85). It is a multi-domain surface-exposed molecule that forms a coiled-
coil secondary structure with significant irregularities that in the B-repeat region are essential 
for the fibrinogen binding properties (86).  Binding of complement factors, fibrinogen and 
inhibition of C3b deposition on the bacterial surface are mechanisms by which the M-protein 
can inhibit opsonization of the organism by the alternative complement pathway, thus 
evading the host's nonspecific immune defense mechanism.  
Several M-like proteins have been identified in group C and G streptococci. Protein MG1, the 
first group G streptococcal M-like protein characterized on the molecular level (87), exhibits 
typical structural and biological features of M proteins, such as coiled-coil structure and the 
ability to generate type-specific opsonizing antibodies. Protein MG1 shares highly 
homologous sequences with the C-terminal repeat region of class I M proteins, which are 
frequently associated with rheumatic fever. M proteins of group G streptococci are also 
responsible for conferring resistance to phagocytosis (88). 
In human strains of group G streptococci, FOG is critical for bacterial pathogenesis through 
its antiphagocytic action of binding fibrinogen (89). It also has the ability to bind IgG 
subclasses IgG1 and IgG2, although FOG-bound IgG1 can actually trigger the complement 
cascade through C1/C1q activation. It is unclear as to whether this is then detrimental to the 
bacteria as FOG remains protective against phagocytosis (90).   
The antiphagocytic protein SeM (FgBP) appears to be the most predominant M-like protein 
on the surface of S. equi, capable of binding fibrinogen and IgG4 and IgG7 subclasses (91-
93). SeM confers resistance to phagocytosis but this also requires the presence of the 
hyaluronic acid capsule (94). Like the M protein of S. pyogenes, SeM is variable at the N-
terminal region suggesting selective pressure (95). Interestingly this does not appear to be the 
case for two other M-like proteins expressed by S. equi; Se18.9 and SzPSe (95). The 
antiphagocytic protein Se18.9 is commonly found in strains of S. equi, but rare for strains of 
S. zooepidemicus (72), and acts by binding to fibrinogen and the complement regulatory 
protein, Factor H (96). SzP proteins are also antiphagocytic and are expressed by both S. equi 
and S. zooepidemicus.  Whole genome sequence analysis of S. zooepidemicus strain H70 
identified a potential M-protein homologue in SzM which resembles SeM in secondary 
structure that consists of a predicted C-terminal coiled-coil (72, 97). The N-terminal of SeM 
is unique to S. equi and binds fibrinogen (93, 98). SzM can also bind fibrinogen but cannot 
bind IgG (99). The M protein of S. canis specifically binds the Fc region of IgG in a non-
opsonic manner (100). 
DemA is a S. dysgalactiae protein with homology to FgBP identified by screening of a 
phagemid expression library (101). The mature DemA protein is 54kDa in size, contains a 
signal sequence, cell wall binding domain and is predicted to have a coiled coil secondary 
structure.  DemA shows greatest homology to the FgBP at the C-terminal end in a region that 
does not participate in fibrinogen binding.  The amino acid motif VSKDLADKL is pres
with the repeat units of both DemA and FgBP suggests the sequence may have an important 
biological function. DemA is able to bind IgG from various animal sources, reminiscent of 
type IIa Ig-binding proteins of S. pyogenes in a domain distinct from the fibrinogen binding 
domain.  Nucleotide sequencing of the demA locus identified an open reading frame upstream 
of demA homologous to mga, a positive regulator of M-protein expression in S. pyogenes 
(101).       
C5a peptidase of S. pyogenes (ScpA) is well known to specifically cleave and inactivate the 
chemoattractant C5a, but it has also recently been shown to cleave the complement factor C3 
and the chemoattractant C3a (102), expanding its impact on immune evasion. ScpA has also 
been identified as an adhesion factor enabling bacteria to adhere to endothelial and epithelial 
cells (102). Homologues of ScpA have been identified in group B Streptococcus (ScpB) and 
group C and G streptococci isolated from humans but not group G streptococci from animals 
(103, 104). Both S. equi and S. zooepidemicus also carry homologous C5a peptidase genes 
(scpE and scpZ respectively). Unlike in S. pyogenes, where scpA is located within the mga 
regulon that includes the emm-gene, the scp genes of group B, C and G streptococci are 
associated with a transposon, suggesting lateral genes transfer between these species (103, 
105).  
The S. pyogenes cell wall envelope proteinase, SpyCEP is another protease that contributes to 
the prevention of phagocytosis through the specific cleavage of interleukin-8 and other 
chemokines to prevent the activation and migration of neutrophils (106, 107). Similar 
enzymes have been identified in S. equi (SeCEP) and S. zooepidemicus (SzoCEP) which 
share 98% identity to each other and 59% identity to SpyCEP (108). SeCEP has been shown 
to cleave both human and equine IL-8 and vaccination with a recombinant portion of SpyCEP 
prevented bacterial dissemination in a murine model of S. equi invasive infection, suggesting 
an important contribution to disease (108).  
 IMMUNOGLOBULIN BINDING AND INACTIVATING PROTEINS 
Streptococcal protein G is a surface molecule associated with the majority of group C and G 
streptococcal isolates of human origin. Protein G interactions with immunoglobulins and 
other host proteins have been the subject of detailed reviews (109-111).  Protein G  is defined 
as a type III IgG Fc receptor and interacts with a wide species range of immunoglobulins, as 
well as human serum albumin, kininogen, and D2-macroglobulin. Protein G exhibits a 
modular structure in which the binding sites for IgG are located within the C-terminal repeat 
region (110-112). The central A/B-repeat region constitutes the binding domain for serum 
albumin, and the N-terminal E region is responsible for interacting with the native form of 
D2-macroglobulin (78).  In contrast to human pathogenic strains of group G streptococci that 
exclusively bind to the native (slow) form of D2-macroglobulin via protein G, animal-derived 
isolates of bovine and equine origin bind the proteinase-complexed (fast) form of the 
molecule. The B1 domain of protein G involved in immXQRJOREXOLQELQGLQJFRQVLVWVRIDQĮ-
KHOL[DQGȕ-strand sheets.  This domain has been used a model structure in numerous 
biochemical studies examining protein folding, protein interaction and synthetic protein 
design (113-115).     
Two protein G-related proteins from a mastitis-causing S. dysgalactiae strain, MIG (116) and 
MAG (117, 118), as well as ZAG (119) from S. zooepidemicus, have been characterized on 
the molecular level.  Like protein G, MAG and ZAG exhibit serum albumin and type III Fc 
receptor activity, whereas protein MIG lacks albumin-binding activity. However, MAG is 
able to bind to immunoglobulins from a greater number of animal sources than protein G.  
MAG, ZAG and MIG also bind to the fast form of D2-PDFURJOREXOLQ7KHĮ2-macroglobulin 
binding region in MIG is not homologous to those of protein G, MAG, ZAG and GRAB.  In 
phagocytosis assays a MIG isogenic mutant strain of S. dysgalactiae are not as resistant to 
opsonization by bovine neutrophils as the parental strain (120). MIG has also recently been 
shown to bind to bovine immunoglobulin A (121) and can inhibit bacterial internalization 
into host cells (122).   
As well as IgG binding proteins, group C and G streptococci can express variants of the S. 
pyogenes IdeS and EndoS, which are IgG-degrading enzymes. While IdeS cleaves the hinge-
region of IgG (123), EndoS removes core IgG glycans (124). Both S. equi and S. 
zooepidemicus express two forms of IdeE and IdeZ, respectively, that are capable of cleaving 
IgG from several different mammalian species (125), although IdeE2/IdeZ2 cleave horse IgG 
with greater efficiency than IdeE/IdeZ (126). EndoS homologues have also been identified in 
S. equi (EndoSe) and S. zooepidemicus (EndoSz) and they share 86-89% sequence identity to 
each other and 70% identity to EndoS of S. pyogenes (127). EndoSd has also been found in S. 
equisimilis with IgG hydrolyzing activity (128) and IdeP was identified in the group C 
S. phocae subsp. phocae that affects marine animals, although its function has not been 
confirmed (129).  
ENZYMES AND TOXINS 
After colonization, adherence and evasion of host immune responses, the dissemination of 
pathogenic streptococci in tissues is regarded to be an important step for the onset and 
development of an invasive disease. One of the factors involved in this process is 
streptokinase, a protein found in groups C, G, and A streptococci (130). The formation of a 
streptokinase/plasminogen complex results in the exposure of the plasminogen active site 
which then catalyses the conversion of other plasminogen molecules into plasmin (131).  
Plasmin is a key serine protease in the fibrinolytic system that is able to break down tissue 
barriers, thereby enabling the dissemination of streptococci. M proteins co-ordinately interact 
with the secreted streptokinase by binding either fibrinogen (132) or plasminogen (133). A 
high level of variation exists within the streptokinase gene, ska, and alleles of ska have been 
associated with tissue trophisms and differing levels of plasminogen activation (134). There 
is some overlap of alleles between human strains of group C and G streptococci and group A 
Streptococcus (135). Streptokinases have been isolated from both human and animal group C 
and group G isolates, and have specificity for the plasminogens of their respective hosts 
(136).  Thus streptokinases from human group A, C and G streptococci isolates have greater 
homology to each other than to animal isolates of group C and G streptococci.  A study by 
Caballero et al., (57) found that the amino acid homology between streptokinases from a 
human and animal S. equisimilis isolates to be only 35%.  Homology between the 
streptokinase from S. equisimilis from equine and porcine origins was only 21%.  The ability 
of streptokinases to cleave plasminogen from specific species may therefore be a critical 
factor in determining the host range of individual streptococcal strains (137). Invasive human 
strains of S. equisimilis have been found to express higher levels of streptokinase and this can 
drive virulence in a murine model of invasive necrotising fasciitis, suggesting an important 
role for streptokinase in disease (138, 139).               
Streptolysin O (SLO) is the prototype of a family of thiol-activated cytolysins produced by 
the genus Streptococcus as well as by other Gram-positive bacteria, including Bacillus, 
Clostridium, and Listeria species (140). The genes coding for SLO of group C and G 
streptococci (S. dysgalactiae) are almost identical to that of S. pyogenes (141). SLO 
homologues have not been described in S. equi. SLO is able to disrupt the cytoplasmic 
membrane of several different eukaryotic cell types that includes erythrocytes, leukocytes, 
macrophages, platelets and epithelial cells. Separate to its pore-forming activity, SLO also 
acts to translocate NADase into host cells (142), which contributes to cytoxicity by depleting 
energy stores. Other functions of these two streptococcal toxins include limiting neutrophil 
responsiveness and potentiating bacterial survival, replication and persistence inside 
keratinocytes, epithelial cells and macrophages which may protect GAS from the immune 
response and antimicrobial therapy (143-147). 
Streptolysin S (SLS) is another cytolysin secreted by groups A, C and G streptococci, 
including the animal-pathogenic S. equi species (148).  Streptolysin S belongs to a distinct 
group of hemolytic toxins that are characterized by their resistance to oxidation and 
sensitivity to trypan blue.  SLS activity results in damage to membranes of various cell-types 
as well as subcellular organelles (149).  In contrast to the 57kDa SLO, SLS is a small 57 
amino acid protein. The gene encoding SLS, sagA, is part of a locus containing 9 open 
reading frames which contain significant homology with genes from bacteriocin loci (150, 
151).  In S. equisimilis, SLS expression is under the control of both the covRS and fasCAX 
two component regulatory systems, which in S. pyogenes have been shown to be involved in 
the regulation of multiple virulence factors (152).  In a mouse infection model, S. equisimilis 
expressing SLS proliferate and induce necrotic lesions at the site of infection, whereas SLS 
negative strains do not, suggesting SLS is an important factor in the development of 
necrotizing fasciitis (150).   
Streptococcal pyogenic toxins (spes) are superantigen genes capable of cross-linking the 
MHC class II on antigen presenting cells to the T cell receptor, leading to proliferation of T 
cells and substantial release of inflammatory cytokines. Eleven superantigen genes have been 
identified in S. pyogenes and they are thought to drive the development of scarlet fever and 
toxic shock syndrome, the latter contributing to high mortality rates following necrotising 
fasciitis. Recent work has also identified a role for superantigens in upper respiratory tract 
infection (153). Homologues of the group A streptococcal superantigens have been identified 
in group C and G streptococci (154). The most commonly found superantigen in S. equismilis 
is speG (spegg or speGdys) (155, 156) and genomic analysis indicates that S. pyogenes and S. 
equisimilis speG genes are orthologues that are direct descendants from a common ancestor 
gene (157). The gene for speG can also be found in S. canis (154).  The role of S. equisimilis 
speG in humans is unclear as the presence of this gene does not correlate with disease 
severity and it does not confer mitogenic activity towards human mononuclear cells, although 
it can stimulate bovine T cells (156, 158, 159). The streptococcal superantigens speA, speC, 
speJ, speK, speH, speL, speM and ssa are found infrequently in S. equismilis and other human 
group C and G streptococci (154, 160-162). 
Homologues of S. pyogenes superantigens speH and speI can be carried by strains of S. equi 
(163) and homologues of speK and speL can be carried by both S. equi and S. zooepidemicus, 
although confusion with the nomenclature meant speK homologous were originally termed 
speLse/seeL/szeL and speL homologous were termed speMse/seem/szeM (154, 164, 165). 
Three additional superantigen genes, termed szeN, szeP and szeF, have been identified in S. 
zooepidemicus only, and are capable of stimulating equine peripheral blood mononuclear 
cells (166). S. dysgalactiae-derived mitogen (SDM) shows homology to speM of S. pyogenes 
and can stimulate human mononuclear cells (154, 167). The majority of the superantigens 
found in S. pyogenes and group C and G streptococci are associated with prophages which 
may drive the lateral transfer of these virulence factors between streptococcal species (72, 
168).  
CONCLUSIONS 
Many recent studies have again highlighted the increasing number of systemic infections 
caused by S. equisimilis, particularly amongst immunocompromised individuals and also 
specific populations and this therefore, suggests that this species will gain even more clinical 
importance in the future.  High nucleotide similarities amongst virulence genes and their 
association with mobile genetic elements supports the hypothesis of extensive horizontal 
gene transfer events between streptococcal species of the pyogenic group. A better 
understanding of the mechanisms of pathogenesis will hopefully be revealed with whole 
genome sequencing and this may therefore impact upon more effective clinical strategies for 
the pyogenic group of streptococci, generally.  
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TABLE 1. Pathogenicity factors of group C and group G streptococci  
PATHOGENENICITY 
FACTORS 
ORGANISM REFERENCE 
Fibronectin Binding Proteins   
FnbA S. dysgalactiae (58) 
FnbB S. dysgalactiae (58) 
GfbA S. dysgalactiae (63) 
FNZ/FNE S. zooepidemicus, S. equi (60, 64) 
FNZ2/FNE2 S. zooepidemicus, S. equi (65, 66) 
SFS S. zooepidemicus, S. equi (67) 
M-like Proteins S. dysgalactiae 
S. equisimilis 
(87, 101, 169) 
FOG S. dysgalactiae (89, 90) 
DemA S. dysgalactiae (101) 
SzM/SeM S. zooepidemicus, S. equi (72, 91-93, 97) 
SzPSe/SzP S. zooepidemicus, S. equi (98) 
Se18.9 S. equi (72, 96) 
ScM S. canis (100) 
Others   
C5a peptidase S. dysgalactiae (104, 170) 
SeCEP/SzoCEP S. zooepidemicus, S. equi (108) 
 
Immunoglobulin binding proteins 
  
Protein G S. dysgalactiae (112) 
MIG S. dysgalactiae (116) 
MAG S. dysgalactiae (118) 
ZAG S. zooepidemicus (119) 
Toxins   
Streptokinase S. dysgalactiae, S. equisimilis (130) 
Streptolysin O S. dysgalactiae, S. equisimilis (141) 
Streptolysin S S. dysgalactiae, S. equisimilis 
S. equi, S. zooepidemicus 
(148, 150) 
Superantigens   
SpeGdys/Spegg/SpeG S. equisimilis, S. canis (155) (154) 
SpeH S. equi (163) 
SpeI S. equi (163) 
SpeK S. equi, S. zooepidemicus, S. equismilis (154, 164, 165) 
SpeL S. equi, S. zooepidemicus, S. equismilis (154, 164, 165) 
SpeM S. equisimilis (171) 
ssa S. equisimilis (171) 
SDM/SpeM S. dysgalactiae (167) 
SpeA S. equismilis (160) 
SpeC S. equismilis (160) 
SzeN S. zooepidemicus (166) 
SzeP S. zooepidemicus (166) 
SzeF S. zooepidemicus (166) 
 
  
TABLE 2.  Species within Lancefield group C and group G streptococci (1) 
___________________________________________________________________________ 
SPECIES    KNOWN SOURCES  LANCEFIELD GROUP
  
 
S. dysgalactiae subs. dysgalactiae Animals     C 
S. dygalactiae subs. equisimilis Humans, animals (rare)  C, G 
S. equi subs. equi   Animals    C 
S. canis    Animal, humans (rare)  G 
S. equi subs. zooepidemicus  Animals, humans   C 
S. phocae    Animals (seal)    C 
S. anginosus group   Humans    A, C, F, G  
 
